文献速递流行病学与生物统计临床试验与 GCP

非劣效试验设计中复合结局风险-获益权衡框架

A framework for considering the risk-benefit trade-off in designing noninferiority trials using composite outcome approaches.
PubMed 文献 · Stat Med · 2020-10-26

针对非劣效试验中非劣效界值难以基于临床与统计共同论证的问题,提出利用复合风险-获益结局(整合疗效、安全性与耐受性)进行设计。复合结局可直接用优效性框架分析,或用于设计阶段选取平衡风险与获益的疗效非劣效界值。引入最大可允许疗效下降(MADE)新指标,其随试验组安全性改善增大而增大,并取决于疗效与安全性结局的关联及对照组疗效率。

要点

  • 复合风险-获益结局可用于非劣效试验设计阶段选择疗效非劣效界值。
  • MADE定义为复合结局无治疗效应时两组疗效的边际差异。
  • MADE随试验组安全性改善增大而增大,并受疗效-安全性关联影响。

核心结论

  • 利用复合风险-获益结局可在设计阶段选择平衡风险与获益的疗效非劣效界值。
  • MADE随试验组安全性改善增大而增大,并取决于疗效与安全性结局的关联及对照组疗效率。

研究设计与样本

  • 提出利用复合风险-获益结局进行非劣效试验设计的框架,复合结局整合疗效、安全性与耐受性等维度。
  • 复合结局可用优效性框架分析,或作为设计阶段选择非劣效界值的工具。
  • 通过数值示例比较复合结局优效性检验与以MADE为非劣效界值的疗效非劣效检验的把握度,并应用于一项结核病治疗试验。

主要发现

  • MADE在试验组安全性改善更大时更大。
  • MADE取决于疗效与安全性结局之间的关联。
  • MADE取决于对照组疗效率。

关键数值与推荐

  • MADE定义为在假定复合结局分布下,使复合结局治疗效应为零时两组疗效的边际差异。

临床怎么用

  • 在非劣效试验设计阶段,可考虑采用复合风险-获益结局框架辅助确定疗效非劣效界值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

When a new treatment regimen is expected to have comparable or slightly worse efficacy to that of the control regimen but has benefits in other domains such as safety and tolerability, a noninferiority (NI) trial may be appropriate but is fraught with difficulty in justifying an acceptable NI margin that is based on both clinical and statistical input. To overcome this, we propose to utilize composite risk-benefit outcomes that combine elements from domains of importance (eg, efficacy, safety, and tolerability). The composite outcome itself may be analyzed using a superiority framework, or it can be used as a tool at the design stage of a NI trial for selecting an NI margin for efficacy that balances changes in risks and benefits. In the latter case, the choice of NI margin may be based on a novel quantity called the maximum allowable decrease in efficacy (MADE), defined as the marginal difference in efficacy between arms that would yield a null treatment effect for the composite outcome given an assumed distribution for the composite outcome. We observe that MADE: (1) is larger when the safety improvement for the experimental arm is larger, (2) depends on the association between the efficacy and safety outcomes, and (3) depends on the control arm efficacy rate. We use a numerical example for power comparisons between a superiority test for the composite outcome vs a noninferiority test for efficacy using the MADE as the NI margin, and apply the methods to a TB treatment trial.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Montepiedra G, Ramchandani R, Miyahara S, et al. A framework for considering the risk-benefit trade-off in designing noninferiority trials using composite outcome approaches. Stat Med. 2020. PMID: 33105524. doi:10.1002/sim.8777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。